

Hematopoietic Cell Transplantation for Epithelial Ovarian Cancer

Policy ID:	HHO-DE-MP-1101
Approved By:	Highmark Health Options – Market Leadership
Provider Notice Date:	
Original Effective Date:	N/A
Annual Approval Date:	10/2022
Last Revision Date:	10/08/2021
Products:	Medicaid
Application:	All participating hospitals and providers
Page Number(s):	1 of 3

Disclaimer

Highmark Health Options medical policy is intended to serve only as a general reference resource regarding coverage for the services described. This policy does not constitute medical advice and is not intended to govern or otherwise influence medical decisions.

POLICY STATEMENT

Highmark Health Options may provide coverage under medical surgical benefits of the Company's Medicaid products for medically necessary hematopoietic cell transplantation for epithelial ovarian cancer.

This policy is designed to address medical necessity guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical circumstances warrant individual consideration, based upon review of applicable medical records.

The qualifications of the policy will meet the standards of the National Committee for Quality Assurance (NCQA) and the Delaware Department of Health and Social Services (DHSS) and all applicable state and federal regulations.

DEFINITIONS

Highmark Health Options (HHO) - Managed care organization serving vulnerable populations that have complex needs and qualify for Medicaid. Highmark Health Options members include individuals and families with low income, expecting mothers, children, and people with disabilities. Members pay nothing to very little for their health coverage. Highmark Health Options currently services Delaware Medicaid: Delaware Healthy Children Program (DHCP) and Diamond State Health Plan Plus members.

PROCEDURES

1. A prior authorization is required.

Several types of malignancies can arise in the ovary; epithelial carcinoma is the most common. Epithelial ovarian cancer forms in the tissues covering the ovary.

Hematopoietic cell transplantation (HCT) involves the intravenous (IV) infusion of allogeneic (donor) or autologous stem cells to reestablish hematopoietic function in individuals whose bone marrow or immune system is damaged or defective. They can be harvested from bone marrow, peripheral blood, or umbilical cord blood and placenta shortly after delivery of neonates.

2. Post-payment audit statement

The medical record must include documentation that reflects the medical necessity criteria and is subject to audit by Highmark Health Options at any time pursuant to the terms of your provider agreement.

3. Place of service: inpatient/outpatient

Experimental/investigational (E/I) services are not covered regardless of place of service.

Hematopoietic cell transplantation for epithelial ovarian cancer is typically an outpatient procedure which is only eligible for coverage as an inpatient procedure in special circumstances, including, but not limited to, the presence of a comorbid condition that would require monitoring in a more controlled environment such as the inpatient setting.

CODING REQUIREMENTS

CPT code	Description
38206	Blood-derived hematopoietic progenitor cell harvesting for transplantation, per collection; autologous.
38240	Hematopoietic progenitor cell (HPC); allogeneic transplantation per donor.
38241	Hematopoietic progenitor cell (HPC); autologous transplantation.

REIMBURSEMENT

Participating facilities will be reimbursed per their Highmark Health Options contract.

POLICY SOURCES

National Comprehensive Cancer Network (NCCN) – 2020

Current NCCN guidelines (v.1.2020) do not address hematopoietic cell transplantation for epithelial ovarian cancer for patients either with newly diagnosed or with relapsed or refractory disease.

References

National Cancer Institute, Surveillance Epidemiology and End Results Program. Cancer Stat Facts: Ovarian Cancer. n.d. Accessed February 10, 2020.

National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. v 1.2020. Accessed January 8, 2021.

Werthmann PG, Kempenich R, Kienle GS. Long-term tumor-free survival in a patient with stage IV epithelial ovarian cancer undergoing high-dose chemotherapy and viscum album extract treatment: A case report. Perm J. 2018;23:18-025.

POLICY UPDATE HISTORY

<Date>	<Event>
--------	---------